Sage Journals: Discover world-class research

Abstract

Acute intermittent porphyria (AIP) results from haplo-insufficient activity of porphobilinogen deaminase (PBGD) and is characterized clinically by life-threatening, acute neurovisceral attacks. To date, liver transplantation is the only curative option for AIP. The aim of the present preclinical nonhuman primate study was to determine the safety and transduction efficacy of an adeno-associated viral vector encoding PBGD (recombinant AAV serotype 5–codon-optimized human porphobilinogen deaminase, rAAV5-cohPBGD) administered intravenously as part of a safety program to start a clinical study in patients with AIP. Macaques injected with either 1×10¹³ or 5×10¹³ vector genomes/kg of clinical-grade rAAV5-cohPBGD were monitored by standardized clinical parameters, and vector shedding was analyzed. Liver transduction efficacy, biodistribution, vector integration, and histopathology at day 30 postvector administration were determined. There was no evidence of acute toxicity, and no adverse effects were observed. The vector achieved efficient and homogenous hepatocellular transduction, reaching transgenic PBGD expression levels equivalent to 50% of the naturally expressed PBGD mRNA. No cellular immune response was detected against the human PBGD or AAV capsid proteins. Integration site analysis in transduced liver cells revealed an almost random integration pattern supporting the good safety profile of rAAV5-cohPBGD. Together, data obtained in nonhuman primates indicate that rAAV5-cohPBGD represents a safe therapy to correct the metabolic defect present in AIP patients.

Get full access to this article

View all access options for this article.

References

Abel

, Deichmann

, Nowrouzi

, et al. (2011). Analyzing the number of common integration sites of viral vectors—new methods and computer programs. Plos One, 6, e24247.

Boutin

, Monteilhet

, Veron

, et al. (2010). Prevalence of serum IGG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther., 21, 704–712.

Davidoff

A.M.

, Gray

J.T.

, Ng

C.Y.

, et al. (2005). Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther., 11, 875–888.

Deybach

J.C.

, Badminton

, Puy

, et al. (2006). European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol. Res., 55 suppl 2, s67–s73.

Dowman

J.K.

, Gunson

B.K.

, Mirza

D.F.

, et al. (2012). Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl., 18, 195–200.

Fagone

, Wright

J.F.

, Nathwani

A.C.

, et al. (2012). Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. Hum. Gene Ther. Methods, 23, 1–7.

Favaro

, Downey

H.D.

, Zhou

J.S.

, et al. (2009). Host and vector-dependent effects on the risk of germline transmission of AAV vectors. Mol. Ther., 17, 1022–1030.

Gabriel

, Eckenberg

, Paruzynski

, et al. (2009). Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med., 15, 1431–1436.

Gao

, Vandenberghe

L.H.

, Alvira

M.R.

, et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol., 78, 6381–6388.

10.

Gao

G.P.

, Lu

, Sun

, et al. (2006). High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J. Virol., 80, 6192–6194.

11.

Johansson

, Nowak

, Moller

, et al. (2004). Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Mol. Ther., 10, 337–343.

12.

Kaeppel

, Beattie

S.G.

, Fronza

, et al. (2013). A largely random AAV integration profile after LPLD gene therapy. Nat. Med., 19, 889–891.

13.

Kim

C.Y.

, Lee

H.S.

, Han

S.C.

, et al. (2005). Hematological and serum biochemical values in cynomolgus monkeys anesthetized with ketamine hydrochloride. J. Med. Primatol., 34, 96–100.

14.

, Malani

, Hamilton

S.R.

, et al. (2011). Assessing the potential for AAV vector genotoxicity in a murine model. Blood., 117, 3311–3319.

15.

Manno

C.S.

, Pierce

G.F.

, Arruda

V.R.

, et al. (2006). Successful transduction of liver in hemophilia by aav-factor ix and limitations imposed by the host immune response. Nat. Med., 12, 342–347.

16.

McMahon

J.M.

, Conroy

, Lyons

, et al. (2006). Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cells Dev., 15, 87–96.

17.

Mingozzi

, and High

K.A.

(2011a). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet., 12, 341–355.

18.

Mingozzi

, and High

K.A.

(2011b). Immune responses to AAV in clinical trials. Curr. Gene Ther., 11, 321–330.

19.

Mingozzi

, Hasbrouck

N.C.

, Basner-Tschakarjan

, et al. (2007). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 110, 2334–2341.

20.

Nakai

, Montini

, Fuess

, et al. (2003). AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet., 34, 297–302.

21.

Nathwani

A.C.

, Gray

J.T.

, Ng

C.Y.

, et al. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor ix expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 107, 2653–2661.

22.

Nathwani

A.C.

, Gray

J.T.

, Mcintosh

, et al. (2007). Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human fix in nonhuman primates. Blood, 109, 1414–1421.

23.

Nathwani

A.C.

, Tuddenham

E.G.

, Rangarajan

, et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in Hemophilia B. N. Engl. J. Med., 365, 2357–2365.

24.

Nowrouzi

, Penaud-Budloo

, Kaeppel

, et al. (2012). Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol. Ther., 20, 1177–1186.

25.

Paneda

, Vanrell

, Mauleon

, et al. (2009). Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum. Gene Ther., 20, 908–917.

26.

Paneda

, Collantes

, Beattie

S.G.

, et al. (2011). Adeno-associated virus liver transduction efficiency measured by in vivo [18f]FHBG positron emission tomography imaging in rodents and nonhuman primates. Hum. Gene Ther., 22, 999–1009.

27.

Paruzynski

, Arens

, Gabriel

, et al. (2010). Genome-wide high-throughput integrome analyses by nrLAM-pcr and next-generation sequencing. Nat. Protoc., 5, 1379–1395.

28.

Pilz

I.H.

, Di Pasquale

, Rzadzinska

, et al. (2012). Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction. Virology, 428, 58–63.

29.

Sardh

, Wahlin

, Bjornstedt

, et al. (2013). High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria. J. Inherit. Metab. Dis. [Epub ahead of print]

30.

Sen

, Balakrishnan

, Gabriel

, et al. (2013). Improved adeno-associated virus (AAv) serotype 1 and 5 vectors for gene therapy. Sci. Rep., 3, 1832.

31.

Soonawalla

Z.F.

, Orug

, Badminton

M.N.

, et al. (2004). Liver transplantation as a cure for acute intermittent porphyria. Lancet, 363, 705–706.

32.

Thunell

, Floderus

, Henrichson

, and Harper

(2006). Porphyria in sweden. Physiol. Res., 55 suppl 2, s109–s118.

33.

Unzu

, Sampedro

, Mauleon

, et al. (2010). Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J. Hepatol., 52, 417–424.

34.

Unzu

, Sampedro

, Mauleon

, et al. (2011). Sustained enzymatic correction by raav-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol. Ther., 19, 243–250.

35.

Yasuda

, Bishop

D.F.

, Fowkes

, et al. (2010). AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function. Mol. Ther., 18, 17–22.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

0.02 MB

0.07 MB

Safety and Liver Transduction Efficacy of rAAV5- cohPBGD in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria

Abstract

Get full access to this article

References

Supplementary Material